APUS.AMEXApimeds Pharmaceuticals Us, INC

DEFM14C: Apimeds Merges with MindWave, Pivots to Digital Assets

Sentiment:

Merger Information Statement 26 February 2026 5:49 PM

📋All filings for Apimeds Pharmaceuticals Us, INC

Apimeds Pharmaceuticals US, Inc. has completed a reverse merger with MindWave Innovations Inc., shifting its strategic focus to institutional digital asset treasury solutions while retaining its biopharmaceutical pipeline.

Delay expectedThe Preferred Stock Conversion and Notes Conversion will not become effective until NYSE American approves the Listing Application, introducing a potential delay.The Board of Directors retains sole discretion to implement or abandon the Reverse Stock Split, which could lead to uncertainty or delays in its execution.The company is required to file a resale registration statement for the convertible notes within 45 days of closing and have it declared effective within 75 days (or 120 days in case of full SEC review); delays beyond these deadlines will result in liquidated damages of 1% of the Redemption Value for each 30-day period.

Capital raiseThe company entered into a Securities Purchase Agreement to issue senior convertible notes in an aggregate principal amount of up to $120,900,000.An initial principal amount of $10,875,000 was made available at closing.An additional $2,175,000 will be funded upon the effectiveness of the resale registration statement.The institutional investor has the right to purchase up to an aggregate of $13,075,000 of additional notes.The investor also has the ability to purchase, subject to mutual consent, any amount remaining under the notes, up to $96,950,000 in additional mutual closings.

Worse than expectedApimeds Pharmaceuticals US, Inc. has a history of recurring losses and received a 'going concern' explanatory paragraph from its independent auditors for the years ended December 31, 2024, and 2023.MindWave Innovations Inc. reported a net loss of $6,588,764 for the six months ended September 30, 2025, a significant decline compared to a net income of $57,824,858 in the prior year period, primarily due to lower unrealized gains from digital assets.The merger results in substantial dilution for existing Apimeds shareholders, with MindWave's former stockholders gaining a 90.9% equity stake in the combined company on an as-converted basis.

Summary

Apimeds Pharmaceuticals US, Inc. (APUS) completed a reverse merger with MindWave Innovations Inc. on December 1, 2025, with MindWave becoming a wholly-owned subsidiary of Apimeds.
MindWave's former stockholders now collectively hold 90.9% of the total issued and outstanding equity securities of the combined company on an as-converted and fully diluted basis.
The merger involved the approval of several corporate actions by consenting stockholders holding approximately 51% of Apimeds' common stock, including a Preferred Stock Conversion, Notes Conversion, a 1-for-10 Reverse Stock Split, a 2024 Equity Incentive Plan share increase to 2,096,679 shares, and the adoption of a new 2025 Equity Incentive Plan.
The Preferred Stock Conversion and Notes Conversion are contingent on NYSE American approval of a new listing application, which is required due to a change in control.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $1,781,255 for the three months ended September 30, 2025, and $4,845,845 for the nine months ended September 30, 2025.
MindWave Innovations Inc. reported a net loss of $6,588,764 for the six months ended September 30, 2025, a significant decrease from a net income of $57,824,858 in the same period of 2024.
MindWave's balance sheet as of September 30, 2025, includes digital assets at fair value of $132,277,073, comprising 1,000 Bitcoin, NILA tokens, and Tether.
The combined entity recognized goodwill of $18,486,810 as a result of the reverse acquisition accounting, where MindWave is identified as the accounting acquirer.
A convertible note financing of up to $120,900,000 was entered into, with an initial funding of $10,875,000 and an additional $2,175,000 expected upon the effectiveness of a resale registration statement.
The Board of Directors retains sole discretion to implement or abandon the Reverse Stock Split.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with caution. While the merger introduces a potentially high-growth digital asset business and provides significant capital, the substantial dilution for existing shareholders, Apimeds' ongoing 'going concern' issues, and the inherent volatility of the digital asset market present considerable risks.

Positives

The merger with MindWave Innovations Inc. provides Apimeds with a new strategic direction into the institutional Digital Asset Treasury (DAT) solutions market, which is a fast-growing segment.
MindWave holds 1,000 Bitcoin, free of encumbrances, in segregated sub-wallets, demonstrating a strong reserve posture in digital assets.
The new 2025 Equity Incentive Plan includes an evergreen provision for annual share increases, which can help attract and retain talent.
MindWave reported a net income of $55,898,357 for the year ended March 31, 2025, indicating prior profitability in its digital asset operations.
Apimeds' cash position increased to $6,986,617 as of September 30, 2025, partly due to $11.9 million net proceeds from its IPO in May 2025, which management believes is sufficient for at least the next 12 months of operations.

Negatives

Apimeds Pharmaceuticals US, Inc. has incurred significant operating losses since inception, with a net loss of $4,845,845 for the nine months ended September 30, 2025, and an accumulated deficit of $9,237,769.
The auditor's report for Apimeds included a going concern explanatory paragraph for the years ended December 31, 2024, and 2023, raising substantial doubt about its ability to continue operations.
MindWave Innovations Inc. reported a net loss of $6,588,764 for the six months ended September 30, 2025, a substantial reversal from the prior year's net income, primarily due to lower unrealized gains from changes in the fair value of digital assets.
The conversion of preferred stock and convertible notes will result in significant dilution for existing Apimeds common stockholders, with MindWave holders collectively owning 90.9% of the combined entity.
MindWave's financial results are highly susceptible to the extreme price volatility of Bitcoin and other digital assets, which can lead to significant fluctuations in reported earnings.
MindWave's assets are concentrated in Bitcoin, exposing the company to greater risk due to lack of diversification.
Apimeds has identified material weaknesses in its internal control over financial reporting, including an absence of controls over journal entries, segregation of duties, and reconciliations.
The biopharmaceutical business (Bio Business) is reliant on a single-source supplier for bee venom, and its intellectual property (Apitox) is based on trade secrets and a license from a related party, not patents, which is difficult to protect.

Risks

Early stages of clinical development for Apitox, with no revenue from product sales yet, making future viability uncertain.
Requirement for substantial additional funding; inability to raise capital could force delays, reductions, or termination of development programs.
Auditor's going concern opinion for Apimeds raises substantial doubt about its ability to continue operations.
Material weaknesses in internal control over financial reporting for Apimeds could adversely affect financial statements and investor confidence.
Reliance on a license from principal stockholder Apimeds Korea for Apitox development; termination of this agreement would materially harm the business.
Potential conflicts of interest among directors and officers who hold positions in both Apimeds and Apimeds Korea/Inscobee Inc.
Limited experience in designing and implementing pivotal clinical trials, which could lead to delays, increased costs, or failure to obtain regulatory approval.
The FDA regulatory approval process is lengthy, unpredictable, and may result in significant delays or denial of approval for Apitox.
Apitox's novel approach to treatment introduces uncertainties regarding development, market acceptance, and third-party reimbursement.
Success in preclinical or earlier clinical trials may not be indicative of results in future clinical trials, and product candidates may fail to receive regulatory approval.
Regulatory approval is limited to specific indications, and off-label promotion could lead to significant penalties.
Expending limited resources on specific product candidates or indications may cause the company to miss more profitable opportunities.
Reliance on third-party manufacturing and a single-source supplier for raw materials (bee venom) creates supply chain risks.
Changes in manufacturing methods or formulation may result in additional costs or delays.
Undesirable side effects or other negative characteristics of product candidates could halt clinical development or limit commercial potential.
Difficulty in establishing a successful in-house sales organization or maintaining effective collaborative arrangements.
Inherent risk of product liability lawsuits, which could result in substantial liabilities or limit commercialization.
Unstable market and economic conditions (e.g., global credit, financial markets, inflation, interest rates) may adversely affect business and stock price.
Health epidemics (e.g., COVID-19) or natural disasters could disrupt operations.
Risk of fraud or other misconduct by employees, principal investigators, consultants, and commercial partners.
Relationships with customers, physicians, and third-party payors are subject to federal and state healthcare fraud and abuse laws, and health information privacy and security laws.
Changes in funding for the FDA and other government agencies could hinder timely product development and approval.
Increasingly stringent and rapidly changing laws and regulations related to privacy and data security (e.g., HIPAA, CCPA, GDPR) could harm reputation and incur fines.
Potential for biosimilar competition for Apitox if approved as a biologic product.
Exposure to the Foreign Corrupt Practices Act (FCPA) and similar anti-bribery laws as business activities expand internationally.
Reliance on trade secrets for Apitox protection, which are difficult to enforce, and lack of patent protection for the API.
No ownership of the Apitox trademark, licensed from Apimeds Korea, and potential for market confusion with similar products.
The price of the company's stock may be volatile, and investors could lose all or part of their investment.
Control by principal stockholders and management may limit the ability of other stockholders to influence corporate matters.
Emerging growth company (EGC) and smaller reporting company (SRC) status may make the common stock less attractive to investors.
Increased costs and management time required for operating as a public company.
Failure to maintain NYSE American listing requirements.
MindWave's quarterly operating results, revenues, and expenses may fluctuate significantly due to Bitcoin price volatility and fair value accounting under ASU 2023-08.
MindWave's limited ability to adjust expenses and reliance on Bitcoin sales to meet liquidity needs exposes it to market volatility.
MindWave's Bitcoin strategy is unproven over the long term and exposes the company to risks associated with Bitcoin's volatility, lack of cash flows, and concentration of assets.
The broader digital assets industry is subject to counterparty and systemic risks, including bankruptcies and regulatory enforcement actions.
The digital assets industry is rapidly evolving, with legal, regulatory, technical, and accounting uncertainty.
The availability of spot Bitcoin ETPs may adversely affect the market price of the company's listed securities by diverting investor demand.
MindWave's Bitcoin strategy subjects it to enhanced regulatory oversight, including potential AML/KYC and money transmitter licensing requirements.
Unregulated nature and lack of transparency of many Bitcoin trading venues pose risks of fraud, security failures, or operational problems.
Cyberattacks or significant disruptions of MindWave's information technology systems could adversely affect its business.

Future Outlook

The company plans to continue advancing Apitox for knee osteoarthritis through a second Phase III trial and investigate its potential use for multiple sclerosis through non-registered corporate sponsorship studies. The digital asset business aims to expand its institutional Digital Asset Treasury (DAT) platform, including onboarding clients, progressing AI-supported yield programs, and developing ClimateTech, AdTech, and InsurTech verticals. Future capital allocation decisions will consider market conditions, risk management, and regulatory considerations. The company expects to incur substantial operating losses for the foreseeable future and may never achieve profitability.

Management Comments

Dr. Vin Menon, CEO of Apimeds Pharmaceuticals US, Inc., is a veteran in the technology services industry, credited with strategic direction behind disruptive technology companies, and has a proven track record of setting up motivated and high-caliber teams.
Dr. Christopher Kim, Chief Medical Officer, is the inventor and developer of Apitox and founder of Apimeds Korea, with extensive experience in pharmaceutical development and autoimmune diseases.
Management believes the progress in clinical trials provides support for the potential of Apitox as an innovative therapy for knee OA and potentially MS.
Management believes the combined structure of the merger enhances the ability to scale client adoption while maintaining regulatory discipline and institutional-grade controls for the DAT platform.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a changing regulatory landscape, with a strong emphasis on intellectual property. The osteoarthritis therapeutics market is projected to grow from $8.28 billion in 2022 to $20.24 billion by 2032, and the MS market from $10.73 billion in 2022 to $24.4 billion by 2030. The digital asset industry is rapidly evolving, with increasing institutional interest in Bitcoin as a treasury asset, but also significant legal, regulatory, and technical uncertainty. The emergence of spot Bitcoin ETPs and central bank digital currencies (CBDCs) is intensifying competition and potentially altering market dynamics for digital assets.

Comparison to Industry Standards

Apimeds' Apitox has completed a positive Phase 3 trial for osteoarthritis in South Korea, where it is approved and marketed, but the prior U.S. Phase III trial did not meet FDA standards due to study population size and data handling, indicating a need for further rigorous clinical investigation to meet global benchmarks.
The company's aim to reduce NSAID and opioid use for OA pain management aligns with a growing trend in healthcare to seek non-addictive alternatives, positioning Apitox favorably if FDA approval is secured.
MindWave's focus on institutional Digital Asset Treasury (DAT) solutions, including compliant Bitcoin treasury infrastructure and AI-driven yield capabilities, positions it in an emerging market segment that is attracting significant institutional capital, as evidenced by the recent approval of U.S. spot Bitcoin ETPs.
MindWave's strategy of holding 1,000 Bitcoin as a core reserve asset is comparable to other public companies that have adopted Bitcoin treasury strategies, such as MicroStrategy, which has made substantial Bitcoin acquisitions, though MindWave's scale is currently smaller.
The projected CAGR of 9.4% for the osteoarthritis therapeutics market and 10.32% for the MS market suggests that Apimeds is targeting high-growth areas within the biopharmaceutical sector, which is competitive but offers substantial market opportunity if products gain approval.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Erik Emerson	Dr. Vin Menon	December 1, 2025	Resignation of previous CEO in connection with the Merger Agreement.
President	NA	Erik Emerson	December 1, 2025	New officer position created in connection with the Merger Agreement.
Director	NA	Amir Dossal	Upon NYSE American approval of Listing Application	Nominated to serve on the Board of Directors.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaw Amendment	Stockholders may no longer take action by written consent; actions must be taken at annual or special meetings.	April 11, 2025	Restricts stockholder ability to force consideration of proposals or take action without a meeting, potentially consolidating power with the Board.
Bylaw Amendment	Only the Chairman of the Board, Chief Executive Officer, or a majority of authorized directors may call special meetings of stockholders.	April 11, 2025	Limits stockholders' ability to call special meetings, further centralizing control over meeting agendas.
Bylaw Amendment	Established advance notice procedures for stockholder proposals and director nominations at annual or special meetings.	April 11, 2025	Increases hurdles for stockholders to propose business or nominate directors, potentially reducing shareholder activism.
Bylaw Amendment	Eliminated cumulative voting rights for stockholders.	April 11, 2025	Reduces the ability of minority shareholders to elect directors, potentially strengthening the position of majority shareholders.
Bylaw Amendment	Bylaws may be amended or repealed by a majority vote of the Board of Directors or by holders of at least 66 2/3% of the voting power of outstanding shares.	April 11, 2025	Provides the Board with significant power to amend bylaws, while requiring a supermajority of stockholders for similar action.
Bylaw Amendment	Designated the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain corporate actions and federal district courts for Securities Act claims.	April 11, 2025	Limits stockholders' choice of forum for certain disputes, potentially making litigation more predictable for the company but less convenient for some plaintiffs.
Committee Appointments	Established Audit, Compensation, and Nominating & Corporate Governance committees, with independent directors appointed.	October 2023 (initial appointments), December 1, 2025 (new CEO/President, Director nominee)	Enhances corporate oversight and compliance with NYSE American listing standards, promoting accountability and transparency.

Legal Proceedings

No material Actions pending or threatened against Apimeds Pharmaceuticals US, Inc. or its subsidiaries as of the date of the Information Statement.
No material Actions pending or threatened against MindWave Innovations Inc. as of the date of the Information Statement.

Related Party Transactions

Apimeds Pharmaceuticals US, Inc. is dependent on a license from its principal stockholder, Apimeds Korea, to continue clinical trials and development of Apitox.
Dr. Christopher Kim, Apimeds' Chairman and Chief Medical Officer, is the founder of Apimeds Korea and contributed to the intellectual property related to Apitoxin.
Mr. Jakap Koo, an Apimeds director, is the Chief Executive Officer and President of Apimeds Korea and its parent company, Inscobee Inc.
Apimeds Pharmaceuticals US, Inc. issued promissory notes to Inscobee Inc. and Apimeds Korea in 2022, 2024, and 2025.
MindWave Innovations Inc. acquired NILA tokens from a related party entity, Calfin Capital, with common control and management.
MindWave's Chief Executive Officer holds joint wallet custody of $16,802,676 in digital assets.

Stakeholder Impact

**Shareholders (Existing Apimeds)**: Significant dilution of ownership and voting interests due to the merger and conversion of preferred stock/notes, with MindWave's former stockholders holding 90.9% of the combined entity. The 1-for-10 reverse stock split will reduce the number of outstanding shares, potentially affecting liquidity.
**Shareholders (MindWave)**: Gain a substantial majority (90.9%) ownership in a publicly traded entity, providing liquidity and access to public markets for their digital asset business.
**Employees (Apimeds)**: The 2024 Plan Share Increase and 2025 Equity Plan provide continued equity incentives, potentially boosting morale and retention. Management changes include a new CEO and President.
**Employees (MindWave)**: Integration into a publicly listed structure, with continued equity incentives under the new 2025 Equity Plan.
**Customers (Apimeds' Bio Business)**: Continued development of Apitox for OA and MS, potentially leading to new treatment options, but subject to lengthy regulatory approval processes.
**Customers (MindWave's DAT Business)**: Access to institutional Digital Asset Treasury solutions, including compliant Bitcoin infrastructure and AI-driven yield programs, under a publicly listed structure, potentially enhancing trust and scalability.
**Suppliers (Apimeds)**: Continued reliance on a single-source supplier for bee venom, posing risks if supply is disrupted.
**Creditors**: The convertible note financing provides significant capital, but the company's historical losses and 'going concern' status for Apimeds indicate ongoing financial risk.

Next Steps

NYSE American approval of the Listing Application for Preferred Stock and Notes Conversion.
Board of Directors' decision on the implementation of the Reverse Stock Split.
Filing of a resale registration statement on Form S-1 for the convertible notes within 45 days of closing and achieving effectiveness within 75-120 days.
Apimeds to pursue a second Phase III trial for Apitox in knee osteoarthritis to meet FDA standards.
Apimeds to conduct non-registered corporate sponsorship studies to identify appropriate MS patient populations, starting in Q1 2025.
MindWave to onboard initial institutional clients to its corporate Bitcoin treasury infrastructure.
MindWave to progress AI-supported, risk-managed yield programs.
MindWave to stand up enterprise validator services.
MindWave to advance development of ClimateTech, AdTech, and InsurTech verticals.
Acquiror to file a registration statement on Form S-8 for the 2024 Equity Incentive Plan share increase within five business days following the Action Effective Time.

Key Dates

Date	Description
2003	Apimeds Korea successfully completed Phase I, Phase II, and Phase III trials in OA, leading to Apitoxin approval by the Korean MFDA.
2003	Apitoxin approved by Korean Ministry of Food and Drug Safety (MFDA) to treat pain and mobility in patients with OA.
2003	Apimeds Korea began post-marketing/approval safety study for Apitoxin in South Korea, following 3,194 patients.
2008	Bitcoin introduced.
2009	Apimeds Korea post-marketing/approval safety study concluded, with no serious adverse events reported.
2013	First of two required U.S. Phase III clinical trials for Apitoxin in OA authorized by FDA.
2014	Apimeds Korea submitted Investigational New Drug Application (IND) 122804 for MS.
2018	Apimeds Korea Phase III OA Trial (330 patients) completed, showing therapeutic effect but not meeting FDA standards due to small population and data handling issues.
2020-05-11	Apimeds Pharmaceuticals US, Inc. incorporated in Delaware.
2020-10	Sponsorship of IND 122804 transferred from Apimeds Korea to Apimeds Pharmaceuticals US, Inc.
2020-12-27	TechyTrade FZ-LLC incorporated in United Arab Emirates.
2021-08-02	Apimeds Pharmaceuticals US, Inc. entered into a business agreement with Apimeds Korea for Apitox license.
2021-08-21	Apimeds, Inc. (Apimeds Korea) and Apimeds Pharmaceuticals US, Inc. entered into a business agreement for pharmaceutical operations.
2021-09-21	Apimeds Pharmaceuticals US, Inc. responded to non-clinical hold comments from the FDA.
2021-10-12	Apimeds Pharmaceuticals US, Inc. entered into an intellectual property assignment agreement with Apimeds Korea and Dr. Christopher Kim.
2021-11-03	Start date of 10-year exclusive supply agreement with Apico, Inc. for bee venom.
2021-11	Apimeds Pharmaceuticals US, Inc. received a clinical hold from the FDA due to the retirement of the former principal investigator.
2022-03-21	Apimeds Pharmaceuticals US, Inc. issued a $160,000 promissory note to Inscobee.
2022-06-03	Apimeds Pharmaceuticals US, Inc. issued a $100,000 promissory note to Inscobee.
2022-09	Ethereum network transitioned to a proof-of-stake mechanism.
2023-02	FDA removed clinical hold on IND 122804, allowing it to be initiated.
2023-09-21	Apimeds Pharmaceuticals US, Inc. signed an executive employee agreement with the CEO, Erik Emerson.
2023-10	Jakap Koo joined Apimeds Pharmaceuticals US, Inc. as a director.
2023-10	Dr. Bennett Weintraub and Carol O'Donnell joined Apimeds Pharmaceuticals US, Inc. as directors.
2023-12-05	Apimeds Pharmaceuticals US, Inc. amended promissory notes to be convertible and extended maturity date to December 31, 2026, or consummation of a qualified offering.
2023-12-05	Apimeds Pharmaceuticals US, Inc. authorized 10,000,000 shares of preferred stock.
2023-12	FASB issued Accounting Standards Update (ASU) No. 2023-08, Accounting for and Disclosure of Crypto Assets.
2024-01-01	MindWave Innovations Inc. adopted ASU No. 2023-07 on Segment Reporting.
2024-01-10	SEC approved applications for listing and trading of spot Bitcoin exchange-traded products (ETPs).
2024-01-11	Trading of spot Bitcoin ETPs commenced.
2024-04	Most recent Bitcoin halving occurred.
2024-04	MindWave Innovations Inc. entered into an exclusive Service Agreement with a Distributor and Service Provider for NILA tokens.
2024-05-20	Apimeds Pharmaceuticals US, Inc. issued a $100,000 promissory note to Inscobee Inc.
2024-08-19	Apimeds Pharmaceuticals US, Inc. issued a $150,000 promissory note to Inscobee Inc.
2024-08	Elona Kogan joined Apimeds Pharmaceuticals US, Inc. as a director.
2024-09-18	Apimeds Pharmaceuticals US, Inc. adopted the 2024 Equity Incentive Plan.
2024-11	FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses.
2025-01-01	Apimeds Pharmaceuticals US, Inc. intends to begin early prosecution of appropriate MS patient populations through non-registered corporate sponsorship studies.
2025-01-23	President Trump issued an executive order titled, Strengthening American Leadership in Digital Financial Technology.
2025-02-07	Apimeds Pharmaceuticals US, Inc. Board approved and implemented a 1-for-2.6 reverse stock split.
2025-03-21	Apimeds Pharmaceuticals US, Inc. issued a $250,000 promissory note to Apimeds Korea.
2025-03-31	TechyTrade (Dubai) acquired 1,000 Bitcoin from MindWave Ltd.
2025-05-12	Apimeds Pharmaceuticals US, Inc. consummated its initial public offering (IPO) of 3,375,000 shares at $4.00 per share.
2025-05-16	Apimeds Pharmaceuticals US, Inc. Board approved the grant of 347,279 stock options and 750,000 shares of common stock to the CEO, and 250,000 shares to the Chief Medical Officer.
2025-05-16	The 2024 Promissory Notes and 2025 Promissory Note were amended to extend the maturity date to May 19, 2026.
2025-05-23	SEC approved rule changes permitting listing and trading of spot ETPs for ether.
2025-07	Erick Frim joined Apimeds Pharmaceuticals US, Inc. as CFO.
2025-07	Spot ETPs for ether began trading.
2025-08-05	Advisor Warrants issued by Apimeds Pharmaceuticals US, Inc.
2025-09	TechyTrade FZ-LLC became a wholly owned subsidiary of TechyTrade Innovations Pte. Ltd.
2025-11-10	Mindwave Innovations Inc. incorporated in Delaware and entered into a Reorganization Agreement and Plan of Share Exchange.
2025-11-13	Amendment to Erik Emerson's employment agreement, increasing annual base salary to $500,000 and detailing severance terms.
2025-11-29	Apimeds Pharmaceuticals US, Inc. Board of Directors adopted a unanimous written consent for the Certificate of Designation of Series A Convertible Preferred Stock.
2025-12-01	Apimeds Pharmaceuticals US, Inc. entered into and closed the Agreement and Plan of Merger with MindWave Innovations Inc., Lokahi Therapeutics, Inc., and Erik Emerson.
2025-12-01	Apimeds Pharmaceuticals US, Inc. entered into a Securities Purchase Agreement with institutional investors for senior convertible notes up to $120,900,000.
2025-12-01	Consenting Stockholders approved the Preferred Stock Conversion, Notes Conversion, Reverse Stock Split, 2024 Plan Share Increase, and 2025 Equity Plan by written consent.
2025-12-01	Erik Emerson resigned as Chief Executive Officer of Apimeds Pharmaceuticals US, Inc. and was appointed President of Apimeds Pharmaceuticals US, Inc.
2025-12-01	Dr. Vin Menon appointed Chief Executive Officer of Apimeds Pharmaceuticals US, Inc.
2025-12-01	Apimeds Pharmaceuticals US, Inc. filed a Certificate of Designation for Series A Convertible Preferred Stock.
2025-12-02	Apimeds Pharmaceuticals US, Inc. filed Current Report on Form 8-K regarding the Securities Purchase Agreement.
2025-12-08	Apimeds Pharmaceuticals US, Inc. and the Investor entered into Amendment No. 1 to the Securities Purchase Agreement.
2025-12-08	Apimeds Pharmaceuticals US, Inc. and the Investor entered into a Registration Rights Agreement.
2025-12-10	Apimeds Pharmaceuticals US, Inc. filed Current Report on Form 8-K regarding the Merger Agreement and Securities Purchase Agreement.
2025-12-10	Apimeds Pharmaceuticals US, Inc. filed a Certificate of Correction to the Certificate of Designation for Series A Convertible Preferred Stock.
2026-01-08	Apimeds Pharmaceuticals US, Inc. entered into Amendment and Exchange Agreement for senior secured convertible notes.
2026-02-11	Schedule 13G filed by Alto Opportunity Master Fund, SPC Segregated Master Portfolio B.
2026-02-26	Record Date for stockholders entitled to receive the Information Statement.
2026-03-05	Information Statement first mailed to stockholders.
2026-03-25	Approximate effective date for Corporate Actions (Preferred Stock Conversion, Notes Conversion, Reverse Stock Split, 2024 Plan Share Increase, 2025 Equity Plan), pending NYSE American approval.
2028	Next Bitcoin halving expected.

Recommendation

hold

The merger with MindWave Innovations Inc. represents a significant strategic pivot for Apimeds, introducing a high-growth, albeit volatile, digital asset business. While Apimeds' legacy biopharmaceutical operations face substantial challenges, including recurring losses and a 'going concern' opinion, the combined entity now possesses a substantial digital asset portfolio and access to new capital. The significant dilution for existing Apimeds shareholders and the inherent risks associated with the digital asset market warrant caution. However, the potential for growth in the institutional digital asset space and the new capital infusion prevent a 'sell' recommendation. Investors should closely monitor the integration of the businesses, the progress of regulatory approvals for both the biopharma and digital asset segments, and the performance of the digital asset business in a highly dynamic market.

Keywords

Biopharmaceutical, Digital Asset Treasury, Bitcoin, Merger, Reverse Stock Split, Convertible Notes, Equity Incentive Plan, Osteoarthritis, Multiple Sclerosis, Apitox, Clinical Stage, SEC Filing, NYSE American, Corporate Governance, Risk Management, Biotech, Fintech, Blockchain, NILA Token, Regulatory Approval, Dilution, Going Concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.